Preclinical Studies of Apogossypolone in Follicular Lymphoma
Author Information
Author(s): Arnold Alan A, Aboukameel Amro, Chen Jianyong, Yang Dajun, Wang Shaomeng, Al-Katib Ayad, Mohammad Ramzi M
Primary Institution: Wayne State University School of Medicine
Hypothesis
Can Apogossypolone effectively inhibit the growth of Follicular Lymphoma cells?
Conclusion
Apogossypolone is a potent therapeutic agent against Follicular Lymphoma, showing significant growth inhibition and apoptosis induction in both cell lines and patient samples.
Supporting Evidence
- ApoG2 inhibited the growth of WSU-FSCCL cells with an IC50 of 109 nM.
- ApoG2 activated caspases-9, -3, and -8, leading to apoptosis.
- In vivo studies showed a significant increase in life span of treated mice.
Takeaway
ApoG2 is a new medicine that helps kill cancer cells in a type of blood cancer called Follicular Lymphoma, making patients live longer.
Methodology
The study involved in vitro testing on Follicular Lymphoma cell lines and in vivo testing using SCID mice xenograft models.
Potential Biases
Potential conflicts of interest due to affiliations with Ascenta Therapeutics.
Limitations
The study did not determine the maximum tolerated dose for ApoG2.
Participant Demographics
Included patients with Follicular Lymphoma and other types of lymphomas.
Statistical Information
P-Value
0.0034
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website